Alpha Tau Medical Ltd. — Form 6-K Summary
Business Context and Reporting Period
Alpha Tau Medical Ltd., an Israeli medical technology company, furnished this Form 6-K for May 2024 on May 13, 2024. The filing reports the Company’s issuance of a press release titled “Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer.”
Financial and Operating Metrics
The filing text does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash-balance, or other financial metrics. It also does not provide financial statements or a defined quarterly reporting period.
Material Changes Versus Prior Comparable Period
The filing announces a clinical and operational development: treatment of the first patient with liver metastases of colorectal cancer using the Company’s Alpha DaRT treatment. The filing text does not provide comparative clinical results, enrollment data, efficacy outcomes, safety findings, or prior-period metrics.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance or quantified outlook is provided.
- No management discussion of revenue expectations, funding needs, or liquidity is included in the filing text.
- The announcement concerns an initial patient treatment; clinical success, regulatory progress, commercialization, and timing remain subject to further development and applicable risks.
- The referenced press release is furnished as Exhibit 99.1, but its substantive text is not included in the provided filing content.
- The information is furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Items
- Review Exhibit 99.1 for the details of the Alpha DaRT treatment, patient status, treatment protocol, and management commentary.
- Verify subsequent clinical data, safety and efficacy results, regulatory milestones, and trial enrollment.
- Review the Company’s latest Form 20-F and interim reports for cash resources, operating expenses, financing requirements, and going-concern or liquidity disclosures.
- Assess the regulatory and commercialization pathway for treating colorectal cancer liver metastases.